Deals
In third cancer deal, EQRx aims to bring down cost of PD-1, PD-L1 inhibitors
Oct 28, 2020 | 1:45 AM GMT
Through its latest deal with CStone, EQRx is looking to bring lower cost PD-1 and PD-L1 inhibitors to market.
EQRx Inc. launched in January with a $200 million series
